Of mice, men and nanoparticle biocoronas: Are in vitro to in vivo correlations and interspecies extrapolations realistic?

Nanomedicine

Volumn 8, Issue 9, 2013, Pages 1357-1359

  Riviere, Jim E ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

biocorona; biodistribution; in vitro in vivo correlation; interspecies extrapolation; nanoparticle; pharmacokinetics; protein corona

Indexed keywords

NANOPARTICLE; LIPID; SMALL INTERFERING RNA;

BASAL METABOLIC RATE; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; BLOOD FLOW; CELL CULTURE; CELL TYPE; CIRCULATION; DRUG DOSAGE FORM; EDITORIAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOMEDICINE; NANOTOXICOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CORONA; PROTEIN STRUCTURE; SPECIES DIFFERENCE; SUSTAINED DRUG RELEASE; CHEMISTRY; DRUG DELIVERY SYSTEM;

DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84891512447     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.129     Document Type: Editorial

References (16)

1. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle protein complex as a biological entity: A complex fluid and surf ace sceicne challenge for the 21st century. Adv. Colloid Interface Sci. 134-135, 167-174 (2007).
2. Nel AE, Madler L, Velego D, et al.: Understanding biophysiochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009).
3. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotech. 7, 779-786 (2012).
4. Riviere JE. Pharmacokinetics of nanomaterials: An overview of carbon nanotubes, fullerenes and quantum dots. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 26-34 (2009).
5. Cedervall T, Lynch L, Lindman S, et al.: Understanding the nanoparticle protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050-2055 (2007).
6. Salvati A, Pitek AS, Monopoli MP, et al.: Transferrin-functionlized nanoparticles lose their targeting capabilities when a biomedicine corona absorbs on the surface. Nat. Nanotech. 8, 137-143 (2013).
7. Lesniak A, Fenaroli F, Monopoli MP, Åberg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 6, 5845-5857 (2012).
8. Monteiro-Riviere NA, Samburg ME, Oldenburg SJ, Riviere JE. Protein binding modulates the cellular uptake of silver nanoparticles into human cells: Implications for in vitro to in vivo extrapolations. Toxicol. Lett. 220, 286-293 (2013).
9. Dell'Orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle protein corona in a body fluid. PLoS One 5, e10949 (2010).
10. Sahneh FD, Scoglio C, Riviere JE. Dynamics of nanoparticle-protein corona complex formation: Analytical results from population balance equations. PLoS One 8, e64690 (2013).
11. Riviere Jr. Comparative Pharmacokinetics, 2nd Edition. John Wiley and Sons, IA, USA (2011).
12. Mahmood I. Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics. J. Pharm. Sci. 99, 2927-2933 (2010).
13. Riviere JE, Martin-Jimenez T, Sundlof SE, Craigmill AL. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory sepceis. J. Vet. Pharmacol. Therap. 20, 453-463 (1997).
14. Boxenbaum H. Interspecies scaling, allometry, physiological times, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10, 201-227 (1982).
15. Lee HA, Leavens T, Mason SE, Monteiro-Riviere NA, Riviere JE Comparison of quantum dot biodistribution with blood-flow limited physiologically-based pharmacokinetic model. Nano Lett. 9, 794-799 (2009).
16. Li M, Al-Jamal K, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 11, 6303-6317 (2010).